再発・難治小児急性リンパ性白血病に対するクロファラビン併用化学療法

DOI Web Site PubMed

書誌事項

タイトル別名
  • Clofarabine-based combination chemotherapy for relapse and refractory childhood acute lymphoblastic leukemia
  • サイハツ ・ ナンチ ショウニ キュウセイ リンパセイ ハッケツビョウ ニ タイスル クロファラビン ヘイヨウ カガク リョウホウ

この論文をさがす

抄録

Clofarabine, one of the key treatment agents for refractory and relapsed acute lymphoblastic leukemia (ALL), achieves a remission rate of approximately 30% with single-agent clofarabine induction chemotherapy. However, a remission rate of approximately 50% was reported with a combination chemotherapy regimen consisting of clofarabine, etoposide, and cyclophosphamide. We treated two cases with refractory and relapsed ALL with combination chemotherapy including clofarabine; one was an induction failure but the other achieved remission. Both cases developed an infectious complication (NCI-CTCAE grade 3) and body pain with infusion. Prophylactic antibiotic and opioid infusions facilitated avoiding septic shock and pain. Further investigation of such cases is required.

収録刊行物

  • 臨床血液

    臨床血液 55 (11), 2316-2319, 2014

    一般社団法人 日本血液学会

キーワード

詳細情報 詳細情報について

問題の指摘

ページトップへ